Prostatic specific antigen in patients with hypogonadism: effect of testosterone replacement.

摘要: ABSTRACT Introduction The effect of parenteral testosterone replacement therapy on prostatic specific antigen (PSA) level or the development growth prostate cancer is unclear. Aim To assess PSA in patients with hypogonadism associated erectile dysfunction (ED). Methods A total 187 male above age 45 ED were enrolled this study. Patients screened for by function domain International Index Erectile Function (IIEF). underwent routine laboratory investigations, plus testosterone, and assessment. Replacement treatment every 2–4 weeks 1 year was instituted. Total serum levels assessed 3 months during course. Results Mean age ± SD 62.8 ± 11.4. Of 87.7% sexually active. 10.2% had mild, 40.6% moderate 49.2% severe ED. study population, 62.5% complaints less than 5 years 84.5% gradual onset their complaint. majority (91.4%) either progressive stationary course while minority reported regressive improvement condition. There a significant increase post‐treatment comparison to pretreatment ( P  > 0.05). No difference between pre‐ categories (normal, borderline, high) relation severity no association duration population Conclusion current demonstrated that not significantly changed after